Cruz Rivera, Samantha
Torlinska, Barbara
Marston, Eliot
Denniston, Alastair K.
Oliver, Kathy
Hoare, Steve
Calvert, Melanie J. http://orcid.org/0000-0002-1856-837X
Funding for this research was provided by:
Research England (Quality-related research)
Article History
Received: 29 September 2020
Accepted: 26 January 2021
First Online: 16 February 2021
Compliance with Ethical Standards
:
: MJC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, a National Institute for Health Research (NIHR) Senior Investigator and receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma. AD receives funding from Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. AKD also receives funding from the Wellcome Trust, and the NIHR Biomedical Resource Centre (Moorfields Eye Hospital/UCL) and the Regulatory Horizons Council. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, the Regulatory Horizons Council or the Department for Business, Energy and Industrial Strategy. KO states that she has no real or perceived conflicts of interests with regard to her co-authorship of this paper but for the sake of transparency she states the following: Between 2005 and 2020, the IBTA has received unrestricted educational grants and financial support and/or support in kind either as an individual organisation or as part of a wider grouping of patient organisations, from the following companies and trusts: AbbVie, Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS) Celldex Therapeutics, Celgene, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), GW Pharmaceuticals, Ivy Foundation (USA), Lilly, Link Pharmaceuticals, MagForce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), STOPheresetumoren.nl, to-BBB, Vane Percy (UK), VBL Therapeutics and the Wallerstein Foundation (USA). Kathy Oliver, on behalf of Kathy Oliver Consulting, has also in this same period received consultancy fees from Lilly, GSK, Bayer, SPAEN and Novartis. For further details of the IBTA’s sponsorship policy, please see ExternalRef removed. SH is an employee of The Association of the British Pharmaceutical Industry.